GRÜNENTHAL ADVANCES PROPRIETARY NOCICEPTIN RECEPTOR (NOP) AGONIST INTO PHASE II TRIAL IN ACUTE PAIN

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Research

More Like This

GRÜNENTHAL SUCCESSFULLY COMPLETES PHASE I TRIAL WITH NOCICEPTIN RECEPTOR (NOP) AGONIST

GRÜNENTHAL'S PROPRIETARY NAV 1.8 INHIBITOR ENTERS CLINICAL DEVELOPMENT

Figure 1: Mean NPRS Over Time in Phase 3 Study of Acute Pain Following Abdominoplasty (Graphic: Business Wire)

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain